drug-eluting stents

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Original title:&nbsp;Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomized, single-blind, multicentre, non-inferiority trial.&nbsp;Reference:&nbsp;Von Birgelen C et al. The Lancet. 2014; Epub ahead of print. In the 3rd generation zotarolimus-eluting stent, platform was modified to increase flexibility and make implant easier in complex lesions. This study was<a href="https://solaci.org/en/2014/02/13/3rd-generation-zotarolimus-eluting-stent-non-inferior-to-everolimus/" title="Read more" >...</a>

Everolimus-eluting stent and DEB in restenosis for BMS. Good results of both with some expected differences.

Original title:&nbsp;A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent In-Stent Restenosis: The RIBS V Clinical Trial.&nbsp;Reference:&nbsp;Fernando Alfonso et al. J Am Coll Cardiol. 2014; Epub ahead of print. &nbsp; Drug-eluting stents (DES) have proven to be superior in terms of restenosis than bare metal stents (BMS). BMS, however due<a href="https://solaci.org/en/2014/01/22/everolimus-eluting-stent-and-deb-in-restenosis-for-bms-good-results-of-both-with-some-expected-differences/" title="Read more" >...</a>

Unprotected trunk in diabetics: angioplasty with good long-term results but more revascularization

Original title:&nbsp;Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: D-DELTA registry.&nbsp;Reference:&nbsp;Meliga Emanuele, et al. EuroIntervention 2013; 9:803-808 Diabetes increases cardiovascular risk events because of their involvement in diffuse form of the vessels, thereby generating more events and changes in revascularization strategy<a href="https://solaci.org/en/2013/12/12/unprotected-trunk-in-diabetics-angioplasty-with-good-long-term-results-but-more-revascularization/" title="Read more" >...</a>

Drug eluting balloon followed BMS versus DES in de novo lesions

Original title:&nbsp;Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial.&nbsp;Reference:&nbsp;Francesco Liistro et al. Am Heart J 2013;166:920-6. Recently, drug eluting balloons (DEB) have emerged as a potential alternative to drug-eluting stents (DES). Paclitaxel is an appropriate drug for DEBs given<a href="https://solaci.org/en/2013/12/03/drug-eluting-balloon-followed-bms-versus-des-in-de-novo-lesions/" title="Read more" >...</a>

Paclitaxel eluting balloon . More effective in restenosis of BMS than DES

Original title:&nbsp;A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.&nbsp;Referencia:&nbsp;Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel &#8211; eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ).<a href="https://solaci.org/en/2013/09/25/paclitaxel-eluting-balloon-more-effective-in-restenosis-of-bms-than-des/" title="Read more" >...</a>

Everolimus Eluting Stent in multiple vessels with short SYNTAX score

Original title:&nbsp;A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial.&nbsp;Reference:&nbsp;Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. Drug-eluting stents (DES ) have emerged<a href="https://solaci.org/en/2013/09/24/everolimus-eluting-stent-in-multiple-vessels-with-short-syntax-score/" title="Read more" >...</a>

Difference in mortality with surgery versus angioplasty in diabetic multivessel patients

Original title:&nbsp;Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: A meta-analysis of randomized controlled trials.&nbsp;Reference:&nbsp;Verma S. et al.&nbsp;Lancet Diabetes Endocrinol. 2013;Epub ahead of print. The FREEDOM study was the last of the randomized studies that compared the results of surgery versus coronary angioplasty in diabetic multivessel patients showing a<a href="https://solaci.org/en/2013/09/18/difference-in-mortality-with-surgery-versus-angioplasty-in-diabetic-multivessel-patients/" title="Read more" >...</a>

Ticagrelor reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective randomized PLATO trial.&nbsp;Reference:&nbsp;Steg PG et al. Circulation. 2013; Epub ahead of print The PLATO study randomized 18624 patients with acute coronary syndrome to receive ticagrelor &nbsp; (180 mg loading dose followed by 90 mg twice daily )<a href="https://solaci.org/en/2013/09/12/ticagrelor-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Rivaroxaban reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51.&nbsp;Reference:&nbsp;C. Michael Gibson et al. J Am Coll Cardiol 2013;62:286&ndash;90. There are few contemporary studies that investigated oral anticoagulation utility in patients with acute coronary syndromes and coronary angioplasty. Rivaroxaban is an oral anticoagulant that directly and<a href="https://solaci.org/en/2013/08/23/rivaroxaban-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Zotarolimus-eluting stent in-stent restenosis

Original title:&nbsp;Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis Two-Year Results From a Pooled Analysis.&nbsp;Reference:&nbsp;Gert Richardt et al. J Am Coll Cardiol Intv 2013, article in press. Previous studies reported a target lesion revascularization (TLR) of 15% and target vessel (TVR) of 22% &nbsp;after a year of treating an injury-stent restenosis.<a href="https://solaci.org/en/2013/08/16/zotarolimus-eluting-stent-in-stent-restenosis/" title="Read more" >...</a>

Top